Table 1 Baseline cohort demographics

n

52

40

12

Age (IQR)

60.8 (50.0–71.0)

60.2 (49.1–70.0)

67.4 (54.2–71.2)

BMI, kg/m²(IQR)

27.4 (23.9–30.9)

27.0 (23.2–32.0

27.7 (24.8–29.7)

Gender, n (%)

Male

23 (44)

14 (38)

5 (36)

Female

29 (56)

25 (63)

7 (64)

Race, n (%)

White

38 (73)

31 (78)

8 (67)

African American

6 (12)

6 (15)

0 (0)

Other

6 (12)

2 (5)

4 (33)

Ejection Fraction (mean ± SD)

60.0 ± 0.09

63.4 ± 0.04

47.90 ± 9.60

Cancer stage, n (%)

I

10 (19)

7 (18)

3 (25)

II

9 (17)

7 (18)

2 (17)

III

12 (23)

10 (25)

2 (17)

IV

10 (19)

7 (18)

3 (25)

Unknown

11 (21)

9 (23)

2 (17)

CVD risk factors

Smoker^*

18 (35)

13 (33)

5 (42)

Hyperlipidemia

19 (37)

14 (35)

5 (42)

Diabetes

13 (25)

8 (20)

5 (42)

Cardiotoxic drugs total mg \((IQR)\) (n)

Radiation

All locations

Total Gy

952.2 (600.8–1355.6)

(7)

1000 (825.4–1062.5)

(3)

Left chest

Total Gy

95,037.5 (60,075–132780)

(4)

0

(0)

Anthracycline

363.5 (240.0–433.2)

(9)

560 (511.6–572.5)

(3)

Trastuzumab

Total mg

(n)

7470.6 (5300–54168)

(12)

3975 (2362.5–5587.5)

(2)

Duration (months)

34 (11.0–44.0)

11.5 (11.25–11.5)

Immunotherapy

Total mg

1400.0

(1)

448.8

(1)

Duration (months)

13

13